Timo Soeterik

126 CHAPTER 7 TABLE 2. Baseline characteristics on prostate lobe level Development ( N = 1774) Validation 1 ( N = 1026) Validation 2 ( N = 938 a ) No EPE at histopatho- logy EPE at histopatho- logy No EPE at histopatho- logy EPE at histopatho- logy No EPE at histopatho- logy EPE at histopatho- logy No. of lobes 1316 458 801 225 790 148 PSA density Median (IQR) Unknown (%) 0.17 (0.12 - 0.17) 19 (1) 0.21 (0.14 – 0.33) 9 (2) 0.16 (0.11 – 0.25) 14 (2) 0.23 (0.14 - 0.43) 8 (4) 0.19 (0.13 – 0.30) 13 (2) 0.21 (0.14 – 0.33) 5 (3) ISUP grade N (%) Benign 1 2 3 4 5 Unknown 341 (26) 365 (28) 296 (22) 93 (7) 58 (4) 36 (3) 127 (10) 31 (7) 65 (14) 147 (32) 75 (16) 58 (13) 71 (16) 11 (2) 213 (26) 315 (39) 119 (15) 54 (7) 22 (3) 12 (2) 66 (8) 10 (4) 54 (24) 79 (35) 33 (15) 27 (12) 13 (6) 9 (4) 204 (26) 306 (39) 151 (19) 55 (7) 27 (3) 17 (2) 30 (4) 9 (6) 38 (26) 41 (28) 20 (14) 21 (14) 17 (11) 2 (1) Percentage positive cores Median (IQR) Unknown N (%) 0.20 (0 – 0.50) 242 (18) 0.67 (0.33 – 1.0) 57 (12) 0.20 (0 – 0.60) 112 (14) 0.80 (0.40 -1.0) 29 (13) 0.33 (0 – 0.60) 47 (6) 0.75 (0.40 – 1.0) 5 (6) Clinical stage assessed by DRE N (%) T1 T2 T3 Unknown 1107 (84) 134 (10) 20 (2) 55 (4) 236 (51) 133 (29) 54 (12) 35 (8) 697 (87) 71 (9) 7 (1) 26 (3) 134 (60) 61 (27) 14 (6) 16 (7) 644 (81) 101 (13) 6 (1) 39 (5) 85 (57) 39 (26) 7 (5) 17 (12) Clinical stage assessed by MRI N (%) No lesion visible Lesion but no EPE EPE Unknown 622 (47) 551 (42) 101 (8) 42 (3) 66 (14) 209 (46) 169 (37) 14 (3) 395 (50) 306 (38) 66 (8) 34 (4) 28 (13) 92 (41) 93 (41) 12 (5) 315 (40) 265 (33) 31 (4) 179 (23) 23 (16) 68 (46) 28 (19) 29 (19) a In this cohort presence of EPE was unknown in one patient / two prostatic lobes. PSA = prostate specific antigen, DRE = digital rectal examination, EPE = extraprostatic extension, IQR = interquartile range, ISUP = International Society of Urological Pathology.